Flight bookings to Hong Kong have fallen 10%, hit by the unrest in the city, said Alan Joyce, the chief executive of Australian carrier Qantas Airways.Airlinesread more
South Korea will scrap an intelligence-sharing pact with Japan amid an intensifying dispute over history and trade, South Korea's presidential office said on Thursday.Asia Politicsread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
Toyota's revolutionary approach to manufacturing turned it from a tiny Japanese automotive latecomer into one of the biggest car companies in the world. But its designs have...Autosread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
diabetes@ (Adds statement from Lexicon, background)
July 26 (Reuters) - French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes.
Shares of Lexicon fell nearly 40% in extended trading.
Sanofi said the termination of the partnership comes after the results of three late-stage studies of the oral drug, Zynquista, which is being jointly developed by the two companies.
In a separate statement, Lexicon said it had not yet received the underlying data from the studies and that it expects to conduct its own review. The company also said it considers Sanofi to be in breach of contract and the termination invalid.
"While we are disappointed in the position taken by Sanofi, we are confident in the strength of the data we have seen thus far in the type 2 diabetes program," Lexicon Chief Executive Officer Lonnel Coats said.
"In the event of a valid termination of the Sanofi alliance, we will also look forward to regaining full rights to Zynquista in type 1 diabetes in the United States, as well as rights in the remainder of the world," he said.
However, Sanofi said trials of the drug will continue without Lexicon.
In March, the U.S. Food and Drug Administration declined to approve the drug for use with insulin in patients with type 1 diabetes, two months after a panel raised concerns of the risk of diabetic ketoacidosis (DKA), leaving them divided over whether the treatment's benefits outweighed the risks.
DKA is a life-threatening condition in which acids called ketones build up when the body starts to use fat instead of glucose as a source of energy.
Zynquista, which contains the active substance sotagliflozin, works by inhibiting the proteins SGLT1 and SGLT2 to help regulate blood glucose levels and reduce the risk of weight gain. (Reporting by Uday Sampath in Bengaluru; Editing by Anil D'Silva)